Resources from the same session
2521 - Safety and Efficacy of the Oral CXCR4 Inhibitor X4P-001 + Axitinib in Advanced Renal Cell Carcinoma Patients: An Analysis of Subgroup Responses by Prior Treatment
Presenter: David McDermott
Session: Poster Discussion 2 – Immunotherapy of cancer
Resources:
Abstract
4181 - Phase 2 study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): results of an interim analysis
Presenter: Chung-Han Lee
Session: Poster Discussion 2 – Immunotherapy of cancer
Resources:
Abstract
2812 - Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis
Presenter: Daniel Catenacci
Session: Poster Discussion 2 – Immunotherapy of cancer
Resources:
Abstract
2794 - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)
Presenter: Haeseong Park
Session: Poster Discussion 2 – Immunotherapy of cancer
Resources:
Abstract
2580 - Analysis of Tumor Hyperprogression (HP) With Nivolumab (Nivo) in Randomized, Placebo (Pbo)-Controlled Trials
Presenter: Martin Reck
Session: Poster Discussion 2 – Immunotherapy of cancer
Resources:
Abstract
Slides
6084 - Early peripheral T-cell responses predict oncological outcome to checkpoint immune blockade in metastatic melanoma
Presenter: Benjamin Fairfax
Session: Poster Discussion 2 – Immunotherapy of cancer
Resources:
Abstract
Poster Discussion 2 – Immunotherapy of cancer - Invited Discussant 1193PD and 1194PD
Presenter: Laurence Buisseret
Session: Poster Discussion 2 – Immunotherapy of cancer
Resources:
Slides
Webcast